A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Date Added
August 10th, 2021
PRO Number
Pro00112310
Researcher
Brian Orr

List of Studies

Keywords
Cancer, Cancer/Gynecological, Drug Studies
Summary

This study is for subjects with ovarian and non-small cell lung cancer. The investigational drug used is XMT-1536 (upifitamab rilsodotin). The drug will be given intravenously "IV" during infusion.
This study will focus on two parts: dose expansion (increasing the dose used) and the pivotal cohort (safety and usefulness of UPLIFT). The purpose of the second part of the study (dose expansion) is to study further the expansion dose (increasing of the dose) of XMT-1536. The research is done based on the data from the first part of the study to ensure that it can be tolerated and is safe. The third part of this study (UPLIFT) will further study the dose recommended in the first part of the study in subjects with ovarian cancer. UPLIFT is used to determine the subjects' response rate to the study drug and the length of time the drug stays in the blood. The subjects will be in the study for 18 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --